Opakalim

N/A

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameOpakalim
Drug Alias Name73H9J7RBA2KB-3061BPN-25203BHV-7000
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium voltage-gated channel subfamily KQT member 3 activatorsVoltage-gated potassium channel subunit Kv7.2 activators
TargetsPotassium voltage-gated channel subfamily KQT member 3Voltage-gated potassium channel subunit Kv7.2
Therapy Area/IndicationsDepressive Disorder, MajorBipolar DisorderErythromelalgia +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[27] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesChannel Biosciences LLC
China Registration ClassN/A

Develop Information

Active CompaniesBiohaven LtdBiohaven Therapeutics LtdYale University +[4] 
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, MajorBipolar DisorderErythromelalgia +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A